ストックスクリーナーアプリを入手
4.92
1.03%
0.05
アフターアワーズ：
4.99
0.07
+1.42%
前日終値:
$4.87
開ける：
$4.81
24時間の取引高:
264.36K
Relative Volume:
0.93
時価総額：
$292.18M
収益：
$30.91M
当期純損益:
$-74.28M
株価収益率:
-4.0384
EPS:
-1.2183
ネットキャッシュフロー:
$-86.15M
1週間 パフォーマンス:
-18.00%
1か月 パフォーマンス:
+1.23%
6か月 パフォーマンス:
-13.23%
1年 パフォーマンス:
-8.72%
1日の値動き範囲:
$4.70
$5.00
1週間の範囲:
$4.70
$5.965
52週間の値動き範囲:
$3.27
$7.61
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
名前
Foghorn Therapeutics Inc
セクター
電話
617-586-3100
住所
500 TECHNOLOGY SQUARE, CAMBRIDGE
Compare FHTX vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FHTX
Foghorn Therapeutics Inc
|
4.92 | 416.29M | 30.91M | -74.28M | -86.15M | -1.2183 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-17 | 再開されました | Jefferies | Buy |
| 2025-12-18 | 開始されました | BTIG Research | Buy |
| 2025-11-07 | 開始されました | Guggenheim | Buy |
| 2025-09-17 | 再開されました | B. Riley Securities | Buy |
| 2025-04-23 | 開始されました | Citizens JMP | Mkt Outperform |
| 2025-01-30 | 開始されました | B. Riley Securities | Buy |
| 2024-09-03 | 開始されました | Jefferies | Buy |
| 2024-08-19 | 開始されました | Evercore ISI | Outperform |
| 2023-03-28 | 開始されました | BofA Securities | Buy |
| 2023-01-05 | 開始されました | BMO Capital Markets | Outperform |
| 2021-11-22 | 開始されました | H.C. Wainwright | Buy |
| 2020-11-17 | 開始されました | Cowen | Outperform |
| 2020-11-17 | 開始されました | Goldman | Buy |
| 2020-11-17 | 開始されました | Morgan Stanley | Overweight |
| 2020-11-17 | 開始されました | Wedbush | Outperform |
すべてを表示
Foghorn Therapeutics Inc (FHTX) 最新ニュース
Stifel reiterates Buy rating on Foghorn Therapeutics stock at $12 By Investing.com - Investing.com South Africa
Stifel reiterates Buy rating on Foghorn Therapeutics stock at $12 - Investing.com
Foghorn Therapeutics (FHTX) Slips 3.5% as Shares Test Key Support Near $5.95Low Vol Factor - Vinanet
Foghorn Therapeutics Inc (NASDAQ: FHTX) Stock Price, News & Analysis - Kalkine
Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy - Yahoo Finance
Foghorn Therapeutics Inc.: Fundamental Analysis and Financial Ratings | FHTX | US3441741077 - marketscreener.com
News Flash: Analysts Just Made A Huge Upgrade To Their Foghorn Therapeutics Inc. (NASDAQ:FHTX) Forecasts - simplywall.st
Enterprise value to EBIT forward of Foghorn Therapeutics Inc. – NASDAQ:FHTX - TradingView
HC Wainwright Issues Negative Outlook for FHTX Earnings - MarketBeat
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - simplywall.st
Wall Street Analysts Believe Foghorn Therapeutics (FHTX) Could Rally 88.47%: Here's is How to Trade - Yahoo Finance
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Wall Street Zen Upgrades Foghorn Therapeutics (NASDAQ:FHTX) to Hold - MarketBeat
Foghorn Therapeutics Reports Q2 Results and Pipeline Progress - The Globe and Mail
BTIG Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Discipline and Rules-Based Execution in FHTX Response - Stock Traders Daily
Foghorn Therapeutics (NASDAQ:FHTX) Issues Earnings Results, Beats Estimates By $0.13 EPS - MarketBeat
Foghorn Therapeutics Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Foghorn Therapeutics advances FHD-909 with Lilly and launches oral immunology program in Q2 update - Traders Union
Foghorn Therapeutics Inc. 2026: Revenue $16.07M, EPS ($0.1) — 10-Q Summary - TradingView
Lilly deal lifts Foghorn Therapeutics (Nasdaq: FHTX) Q2 2026 revenue and cuts loss - Stock Titan
Foghorn’s lung cancer trial advances; IND targeted for 2027 - stocktitan.net
Foghorn Therapeutics (FHTX) Jumps 5.4% as Biotech Stock Approaches Key Resistance at $5.10Combination Correction - dars.gov.et
Foghorn Therapeutics (FHTX) Rises 1.77% as Shares Hold Above Key Support at $4.38Dividend Arbitrage - dars.gov.et
Foghorn Therapeutics (FHTX) Slides 4.4% to $4.53, Approaching Key Support LevelRounding Bottom - dars.gov.et
Foghorn Therapeutics Inc expected to post a loss of 26 cents a shareEarnings Preview - TradingView
Foghorn Therapeutics (FHTX) Declines 6.4% as Gene Regulation Biotech Tests Key Support at $4.21Force Index - vinanet.vn
FHTX Q1 2026 Earnings: Narrower-than-Expected Loss as Pipeline AdvancesProfit Recovery Report - vinanet.vn
Foghorn Therapeutics Inc. (FHTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Foghorn Therapeutics (FHTX) Expected to Release Earnings on Tuesday - MarketBeat
Foghorn Therapeutics Inc. (FHTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
FHTX|Foghorn Therapeutics Inc.|Price:4.880|Chg%:+0.020 - TradingKey
Price to sales forward of Foghorn Therapeutics Inc. – NASDAQ:FHTX - TradingView
Enterprise value to revenue forward of Foghorn Therapeutics Inc. – NASDAQ:FHTX - TradingView
Foghorn Therapeutics Inc. (FHTX) Cash Flow - TradingKey
Foghorn Therapeutics Inc. (FHTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
FHTX|Foghorn Therapeutics Inc.|Price:4.850|Chg%:-0.220 - TradingKey
TradingKey - TradingKey
Foghorn Therapeutics Faces Sell-Off, Tests Key Support at $4.61ATR Stop - Vinanet
(FHTX) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
FHTXFoghorn Therapeutics Inc Options - Finviz
FHTX SEC FilingsFoghorn Therapeutics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Foghorn Therapeutics (FHTX) Surges 5.8%: Is This an Indication of Further Gains? - Yahoo Finance
We're Keeping An Eye On Foghorn Therapeutics' (NASDAQ:FHTX) Cash Burn Rate - Moomoo
Step Pharma announces the appointment of Neil Gallagher as Non-Executive Director - Investing News Network
Step Pharma announces the appointment of Neil Gallagher as Non-Executive Director - GlobeNewswire Inc.
Foghorn Therapeutics Inc.(NasdaqGM: FHTX) dropped from Russell 2000 Value Benchmark - marketscreener.com
Foghorn Therapeutics Inc.(NasdaqGM:FHTX) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Foghorn Therapeutics Inc.(NasdaqGM:FHTX) dropped from Russell 3000E Value Benchmark - marketscreener.com
Foghorn Therapeutics (FHTX) Rises 4.71% as Biotech Stock Tests Key Resistance at $4.43Daily Profile - dars.gov.et
Foghorn Therapeutics Inc (FHTX) 財務データ
収益
当期純利益
現金流量
EPS
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):